{'52WeekChange': 0.020979047,
 'SandP52WeekChange': 0.0644362,
 'address1': '117 Kendrick Street',
 'address2': 'Suite 500',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 1.46,
 'askSize': 41800,
 'averageDailyVolume10Day': 3635087,
 'averageVolume': 8298820,
 'averageVolume10days': 3635087,
 'beta': 1.207843,
 'beta3Year': None,
 'bid': 1.44,
 'bidSize': 40000,
 'bookValue': 0.757,
 'category': None,
 'circulatingSupply': None,
 'city': 'Needham',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 1.4978,
 'dayLow': 1.36,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -1.341,
 'enterpriseToRevenue': 7.739,
 'enterpriseValue': 161296576,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 1.6454285,
 'fiftyTwoWeekHigh': 4.67,
 'fiftyTwoWeekLow': 0.83,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 134487099,
 'forwardEps': -0.49,
 'forwardPE': -2.9795918,
 'fromCurrency': None,
 'fullTimeEmployees': 135,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.06722,
 'heldPercentInstitutions': 0.28229,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/verastem.com',
 'longBusinessSummary': 'Verastem, Inc., a biopharmaceutical company, focusing '
                        'on developing and commercializing medicines to '
                        'improve the survival and quality of life of cancer '
                        'patients. It markets COPIKTRA (duvelisib), an oral '
                        'inhibitor of phosphoinositide 3-kinase (PI3K) and '
                        'dual inhibitor of PI3K-delta and PI3K-gamma, which is '
                        'indicated for the treatment of adult patients with '
                        'relapsed or refractory chronic lymphocytic '
                        'leukemia/small lymphocytic lymphoma after at least '
                        'two prior therapies and relapsed or refractory '
                        'follicular lymphoma (FL) after at least two prior '
                        'systemic therapies. The indication in FL is approved '
                        'under accelerated approval based on overall response '
                        'rate. In addition, it is developing the focal '
                        'adhesion kinase inhibitor defactinib, which is being '
                        'investigated in combination with immunotherapeutic '
                        'agents for the treatment of various different cancer '
                        'types, including pancreatic cancer, ovarian cancer, '
                        'non-small cell lung cancer (NSCLC), mesothelioma, and '
                        'other solid tumors. Verastem, Inc. has collaboration '
                        'agreements with Yakult Honsha Co., Ltd. and CSPC '
                        'Pharmaceutical Group Limited. The company was founded '
                        'in 2010 and is headquartered in Needham, '
                        'Massachusetts.',
 'longName': 'Verastem, Inc.',
 'market': 'us_market',
 'marketCap': 237299648,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_115881768',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -149096992,
 'nextFiscalYearEnd': 1640908800,
 'open': 1.43,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -1.13,
 'phone': '781-292-4200',
 'previousClose': 1.38,
 'priceHint': 4,
 'priceToBook': 1.9286658,
 'priceToSalesTrailing12Months': 11.386193,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 1.4978,
 'regularMarketDayLow': 1.36,
 'regularMarketOpen': 1.43,
 'regularMarketPreviousClose': 1.38,
 'regularMarketPrice': 1.43,
 'regularMarketVolume': 4496268,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 158604992,
 'sharesPercentSharesOut': 0.053200003,
 'sharesShort': 8648045,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 8811503,
 'shortName': 'Verastem, Inc.',
 'shortPercentOfFloat': 0.0602,
 'shortRatio': 1.19,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'VSTM',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.793,
 'twoHundredDayAverage': 2.083885,
 'volume': 4496268,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.verastem.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02494'}